§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US6254573B1 Expired / Lapsed US ⏱️ 0.0 years remaining

Intracardiac drug delivery device utilizing spring-loaded mechanism

Assignee: Biosense Webster Inc
•
Filing: 1999-08-26
•
Granted: 2001-07-03
•
Expires: 2019-08-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An apparatus for intracardiac drug administration of a therapeutic drug comprises a catheter having a distal end and a drug delivery device which is driveable from the distal end. The drug delivery device includes a needle and a spring-loaded mechanism operatively connected to the needle. The spring-loaded mechanism drives the needle out of the distal end of the catheter upon administering of the therapeutic drug. The spring-loaded mechanism returns the needle within the distal end of the catheter after the administering of the therapeutic drug.

Inventors

  • 👤 Shlomo Ben Haim
  • 👤 Uri Yaron
  • 👤 Avraham Matcovitch

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 10:59
CPC Classifications
A; A61; A61M; A61M25/00; A61M25/0067; A61M25/0082; A61M25/0074; A61M25/0075; A61M25/0084; A61B; A61B17/00; A61B17/00234; A61B2017/00238; A61B2017/00243; A61B2017/00247; A61B18/00; A61B2018/00315; A61B2018/00345; A61B2018/00351; A61B2018/00392; A61M2025/0076; A61M2025/0089; A61M2210/00; A61M2210/12; A61M2210/125

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 120 words
An apparatus for intracardiac drug administration of a therapeutic drug comprising: a catheter having a distal end and a drug delivery device driveable from said distal end, said catheter including at least one position sensor which generates position sensor signals responsive to the position of said catheter within a heart, said position sensor signals being used to generate position and orientation coordinates; and said drug delivery device including a needle and a spring-loaded mechanism operatively connected to said needle, said spring-loaded mechanism driving said needle out of said distal end of said catheter upon administering of said therapeutic drug and said spring-loaded mechanism returning said needle within said distal end of said catheter after said administering of said therapeutic drug.
Claim 2
Independent Claim 120 words
An apparatus for intracardiac drug administration of a therapeutic drug comprising: a catheter having a distal end and a drug delivery device driveable from said distal end, said catheter including at least one position sensor which generates position sensor signals responsive to the position of said catheter within a heart, said position sensor signals being used to generate position and orientation coordinates; and said drug delivery device including a needle and a spring-loaded mechanism operatively connected to said needle, said spring-loaded mechanism driving said needle out of said distal end of said catheter upon administering of said therapeutic drug and said spring-loaded mechanism returning said needle within said distal end of said catheter after said administering of said therapeutic drug.
Claim 3
Dependent Claim 20 words
The apparatus according to claim 1 , further comprising a therapeutic drug, wherein the therapeutic drug comprises a growth factor.
Claim 4
Dependent Claim 19 words
Apparatus according to claim 1 , further comprising a therapeutic drug, wherein the therapeutic drug comprises a liquid compound.
Claim 5
Dependent Claim 19 words
Apparatus according to claim 1 , further comprising a therapeutic drug, wherein the therapeutic drug comprises a soluble compound.
Claim 6
Dependent Claim 22 words
Apparatus according to claim 1 , further comprising a therapeutic drug, wherein the therapeutic drug comprises a gene encoding a growth factor.
Claim 7
Dependent Claim 18 words
Apparatus according to claim 1 , further comprising a therapeutic drug, wherein the therapeutic drug comprises naked DNA.
Claim 8
Dependent Claim 13 words
Apparatus according to claim 6 , wherein the therapeutic drug comprises plasmid DNA.
Claim 9
Dependent Claim 19 words
Apparatus according to claim 1 , further comprising a therapeutic drug, wherein the therapeutic drug comprises an adenoviral vector.
Claim 10
Dependent Claim 17 words
Apparatus according to claim 2 , wherein the growth factor comprises a vascular endothelial growth factor (VEGF).
Claim 11
Dependent Claim 16 words
Apparatus according to claim 2 , wherein the growth factor comprises a fibroblast growth factor (FGF).

References Cited (Backward Citations)

US4588395A Cited
US4332893A Cited
US4378347A Cited
US4296100A Cited
US4578061A Cited
US4353888A Cited
US4636195A Cited
US4698301A Cited
US4503038A Cited
US4891225A Cited
US4699788A Cited
US4668226A Cited
US4824436A Cited
US4721672A Cited
US4916073A Cited
US4769362A Cited
US4888324A Cited
US5026839A Cited
US4778787A Cited
US5073492A Cited
US4871356A Cited
US4966847A Cited
US4940730A Cited
US4874746A Cited
US5641743A Cited
US4879312A Cited
US4895838A Cited
US5588432A Cited
US4900673A Cited
US4921482A Cited
US5580859A Cited
US5693622A Cited
US5698531A Cited
US5328470A Cited
US5707969A Cited
US5332671A Cited
US5112946A Cited
US5219739A Cited
US5194596A Cited
US5195968A Cited
US5587383A Cited
US5383923A Cited
US5310883A Cited
US5470831A Cited
US5674192A Cited
US5661133A Cited
US5661133B1 Cited
US5244460A Cited
US5368592A Cited
US5466596A Cited
US5318957A Cited
US5531780A Cited
WO1994011506A1 Cited
US5368564A Cited
US5522815A Cited
EP0618225A1 Cited
WO1995001138A1 Cited
US5568809A Cited
US5641756A Cited
US5385148A Cited
US5431168A Cited
US5733727A Cited
US5602301A Cited
US5404297A Cited
WO1995025807A1 Cited
WO1995029993A1 Cited
WO1996005768A1 Cited
US5652225A Cited
EP0710657A1 Cited
WO1996018303A1 Cited
US5843742A Cited
US5792453A Cited
WO1996026742A1 Cited
US5607918A Cited
US5780052A Cited
US5840059A Cited
US5797870A Cited
WO1996039830A1 Cited
US5807556A Cited
WO1997011720A1 Cited
US5830879A Cited
WO1997014307A1 Cited
WO1997023256A1 Cited
WO1997024981A2 Cited
US5858351A Cited
US5846528A Cited
WO1997029701A1 Cited
WO1997032990A1 Cited
US5785965A Cited
WO1997047253A1 Cited
WO1998005307A1 Cited
WO1998007878A2 Cited
WO1998010085A2 Cited
WO1998015575A1 Cited
US5845646A Cited
US5925012A Cited
US6055453A Cited
WO1999010485A1 Cited
WO1999010014A2 Cited
US5964757A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2004-07-02 2005-01-01 2005-07-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2008-07-02 2009-01-01 2009-07-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2012-07-02 2013-01-01 2013-07-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag